Domestic Data Foreign Data PMS Pivotal dose-response IIa PK / PD

Slides:



Advertisements
Similar presentations
Equivalence Tests in Clinical Trials
Advertisements

Matthew M. Riggs, Ph.D. metrum research group LLC
1 Case Studies in Modeling and Simulation Discussion Stella G. Machado, Ph.D. Office of Biostatistics/OTS/CDER/FDA FDA/Industry Workshop, September 2006.
Robert T. O’Neill, Ph.D. Director, Office of Biostatistics CDER, FDA
1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.
Clinical Pharmacokinetics
Use of Foreign Data for Approval Ann Farrell, MD Division of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration.
ICH E-5 Overview and Current Topics Mamoru Narukawa.
Drug Development in Asia – an Industry perspective Stephen UdenPfizer Inc.
K. Shimatani/ K-H Symposium/ October 22-23, What Impact Will Globalization Have on Bridging Studies Katsuyoshi Shimatani J-Clin, Pfizer.
Problem of the Week! Max was in charge of getting the equipment for the 14 people on his baseball team. He made sure he had 8 bats and 38 baseballs. He.
Traditional Process First in Human Single Ascending Dose Multiple Ascending Dose U.S.A. Japan Phase II Phase III NDA in Japan Phase II Phase III NDA in.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
2003 0ctoberPharsight Copyright 1 Bridging Strategies using Clinical Trial Simulations D. Russell Wada Mountain View CA, USA The 4th Kitasato University-Harvard.
Xavier University of Louisiana College of Pharmacy Curriculum Map – Program Outcomes Map by Course.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
1 ACI Life Sciences Mergers & Acquisitions – March 12, 2009 ASENT INTERNATIONAL SYMPOSIUM ~ Acceptability of Foreign Data~ February 26, 2011 February 26,
Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Warm Up Write each fraction in the simplest form
Required steps Clinical protocol preparation Informed consent Approval of the ethical committee Phase I Healthy volunteers Objectives: 1 - To identify.
1 Vaccine Development: From the Lab to the Clinic Jim Tartaglia, PhD Vice-President, R & D Sanofi Pasteur AIDS Vaccine 2011 Bangkok, Thailand September.
Dr. Mike Ferris Clinical Data for JNDA based on Bridging Japanese Data PK/PD data Bridging trial Foreign Data PK/PD data Trial to compare with bridging.
Historical perspective It all started with Aspirin….
Ichiro Fujisaki Ambassador of Japan Asia in the Coming Years: A Japanese Perspective.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
DOSE SELECTION FOR ANTI-INFECTIVE DRUGS: INDUSTRY PERSPECTIVE
1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.
Regulatory Aspects of PK/PD – (modelling) Karolina Törneke Senior expert, member of the CVMP.
Ameeta Parekh, Ph.D. CDER/OCPB CPSC Meeting November 17/18
TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.
Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
The Globalization of Clinical Development Technology - Current Status & NTRM - Sang - Goo Shin, MD. PhD SNU. Coll. Med. February 26, 2003.
The Stages of a Clinical Trial
Prof. Dr. Basavaraj K. Nanjwade
Prof. Dr. Basavaraj K. Nanjwade M. Pharm., PhD
Benjamin Brown Daven Bryner Zach Orme
Distance and Midpoint Formulas
Miami Plan Requirements
Japan’s Place in the World
Visit for more Information: %284PK%29+-+New+Compatible+Inkjet+Cartridges.
Concepts of Paediatric Investigation Plans (PIP)
Clinical Drug Development
DVP, WW Clinical Research
I like a lot of different films. Most of all I like the film “pk”
סמים וסינפסות.
Section 3: International Economics
Simone M. Shurland, Ph.D., Division of Anti-Infective Products
ФОНД ЗА РАЗВОЈ РЕПУБЛИКЕ СРБИЈЕ
افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی
افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی
תקנות בריאות העם (איכותם התברואית של מי שתייה ומתקני מי שתייה) התשע"ג
A.E. Muller, U. Theuretzbacher, J.W. Mouton 
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Type and Amount of Information Provided Johan E. Wallin, Lena.
FX006 Pivotal Ph 2b Data September , 2015
'III \-\- I ', I ,, - -
My typical day as a scientist in pre-clinical at AZ/MedI
All Star Baseball Academy Conroe, Texas
Yang Liu, Anne Chain, Rebecca Wrishko,
Which is bigger 3 5
© T Madas.
What shapes can you make using the tangram pieces?
,, 'III \-\-
Relative potency of Drugs
Clinical Development Process in ICH E5 Environment (1)
3rd GD Geometry 101 Review Game
Quantitative Decision Making (QDM) in Phase I/II studies
Presentation transcript:

Domestic Data Foreign Data PMS Pivotal dose-response IIa PK / PD Personal Perspective on Bridging Domestic Data Foreign Data PMS Pivotal dose-response IIa PK / PD

“Bridge” is one of many bridges in the development of a new drug “Bridge” is one of many bridges in the development of a new drug. It is not bigger, but rather smaller. Non-Clinical Clinical I IIa IIb III

PK parameter Clinical endpoint Dose PD parameter

Analysis of Dissimilarity Dose PK parameter Clinical endpoint PD parameter  Clinical endpoint  Clinical endpoint  PD  PK = . .  Dose  PD  PK  Dose

Bridging in Baseball Batting Average Japan U.S. Ichiro Ichiro Shinjo 0.400 Ichiro 0.380 0.360 Ichiro 0.340 0.320 Japan U.S. 0.300 0.280 Shinjo Shinjo 0.260 0.240 0.220 0.200